专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080060090A1 Transgenic Mice Inducing Alzheimer's Disease Expressing Mutant Betactf99 审中-公开
标题翻译：转基因小鼠诱导表达突变体Betactf99的阿尔茨海默病
公开(公告)号：US20080060090A1
公开(公告)日：2008-03-06
申请号：US10593672
申请日：2005-04-01
申请人： Pyung Lim Han , Kang-Woo Lee , Sung-si Yang , Jin-Sook Song
发明人： Pyung Lim Han , Kang-Woo Lee , Sung-si Yang , Jin-Sook Song
IPC分类号： A01K67/00 , C12N15/00
CPC分类号： A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2267/0312 , C12N15/8509
摘要： The present invention is related to a transgenic animal inducing Alzheimer's disease. More particularly, the present invention is a vector for transformation of animal comprising a carboxyl-terminal fragments of mutant human beta amyloid protein which contains Indiana mutation (βCTF99) and a transgenic mouse inducing Alzheimer's disease prepared by microinjection of the same into a pronuclei of a fertilized oocyte. The transgenic mouse of the present invention exhibited clinical symptoms of Alzheimer's disease such as decreased of cognitive ability and memory, and increases of anxiety. Therefore, the transgenic mouse of the present invention will be useful animal model for a research of Alzheimer's disease. Particularly, since the transgenic mouse of the present invention showed more remarkable decreases of cognitive ability than any other transgenic animal model for Alzheimer's disease known in the art, the transgenic mouse of the present invention can be used as an animal model for disease relating anxiety.
摘要翻译：本发明涉及一种诱导阿尔茨海默病的转基因动物。更具体地，本发明是用于转化动物的载体，其包含含有印第安纳突变（βCTF99）的突变型人β淀粉样蛋白的羧基末端片段和通过将其显微注射到原核中制备的诱导阿尔茨海默氏病的转基因小鼠受精卵母细胞。本发明的转基因小鼠表现出阿尔茨海默病的临床症状，例如认知能力和记忆力下降，焦虑程度增加。因此，本发明的转基因小鼠将是阿尔茨海默病研究的有用的动物模型。特别地，由于本发明的转基因小鼠比本领域已知的阿尔茨海默病的任何其它转基因动物模型显示出更显着的认知能力降低，所以本发明的转基因小鼠可用作与焦虑相关的疾病的动物模型。

2. 发明申请

US20110098360A1 ADAMANTANE DERIVATIVE FOR INHIBITING TOXICITY OF AMYLOID OLIGOMER 审中-公开
标题翻译：用于抑制AMYLOID低聚物毒性的ADAMANTANE衍生物
公开(公告)号：US20110098360A1
公开(公告)日：2011-04-28
申请号：US12935244
申请日：2009-03-09
申请人： Min Yung Lee , So-Yeop Han , Jun Mo Chung , Pyung Lim Han , Jung Min Koh , Ha Yan Oak , Eun Kyung Hwang , In Sun Baek
发明人： Min Yung Lee , So-Yeop Han , Jun Mo Chung , Pyung Lim Han , Jung Min Koh , Ha Yan Oak , Eun Kyung Hwang , In Sun Baek
IPC分类号： A61K31/132 , C07C211/19 , A61P25/28 , A61P25/16 , A61P25/00 , A61P27/02
CPC分类号： A61K31/132
摘要： Disclosed is a pharmaceutical composition containing a compound useful for inhibiting neurotoxicity caused by beta amyloid. The pharmaceutical composition of the present disclosure contains 1,3,5,7-tetrakis(aminomethyl)adamantane, an analogous compound thereof or a salt thereof as an active ingredient. The inventors have studied methods for reducing the toxicity of beta amyloid oligomers based on the formation mechanism of dodecamers in consideration of the fact that especially the dodecamers from among the beta amyloid oligomers exhibit a significant activity as a toxin for synapses and neurons in cranial nerve diseases. The inventors have confirmed that the disclosed compound can induce structural epitope deformation of the dodecamer and thereby reduce toxicity of the beta amyloid oligomers. The pharmaceutical composition containing the compound is useful for preventing and treating cranial nerve diseases developed by the toxicity of beta amyloid oligomers, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, macular degeneration, prion disease, and the like (see FIG. 1).
摘要翻译：公开了含有可用于抑制由β淀粉样蛋白引起的神经毒性的化合物的药物组合物。本公开的药物组合物含有1,3,5,7-四（氨基甲基）金刚烷，其类似的化合物或其盐作为活性成分。本发明人研究了基于十二烷基化物形成机制降低β淀粉样蛋白低聚物的毒性的方法，考虑到特别是β淀粉样低聚物中的十二烷基化剂作为颅神经疾病中突触和神经元的毒素显示出显着的活性。发明人已经确认所公开的化合物可以诱导十二聚体的结构表位变形，从而降低β淀粉样寡聚物的毒性。含有该化合物的药物组合物可用于预防和治疗由β-淀粉样蛋白寡聚物（例如阿尔茨海默氏病，帕金森病，亨廷顿舞蹈病，黄斑变性，朊病毒病等）的毒性引起的颅神经疾病（见图1 ）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式